Have a feature idea you'd love to see implemented?
Let us know!
XFOR X4 Pharmaceuticals Inc
Price (delayed)
$0.3684
Market cap
$62.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.08
Enterprise value
$43.62M
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4
Highlights
X4 Pharmaceuticals's gross profit has soared by 113% from the previous quarter
The revenue has surged by 99% since the previous quarter
X4 Pharmaceuticals's net income has plunged by 195% from the previous quarter but it has soared by 85% YoY
The EPS has dropped by 189% since the previous quarter but it has soared by 89% year-on-year
The equity has contracted by 37% from the previous quarter and by 12% YoY
The debt has grown by 34% YoY
Key stats
What are the main financial stats of XFOR
Market
Valuations
Earnings
Shares outstanding
170.55M
Market cap
$62.83M
Enterprise value
$43.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.04
Price to sales (P/S)
65.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.84
Revenue
$1.12M
EBIT
-$8.32M
EBITDA
-$6.16M
Free cash flow
-$132.97M
Per share
Balance sheet
Liquidity
EPS
-$0.08
Free cash flow per share
-$0.66
Book value per share
$0.35
Revenue per share
$0.01
TBVPS
$0.75
Total assets
$178.17M
Total liabilities
$118.54M
Debt
$78.2M
Equity
$59.62M
Working capital
$113.71M
Debt to equity
1.31
Current ratio
4.89
Quick ratio
4.65
Net debt/EBITDA
3.12
Margins
Efficiency
Dividend
EBITDA margin
-548.2%
Gross margin
55.9%
Net margin
-1,492.3%
Operating margin
-2,305%
Return on assets
-10.3%
Return on equity
-32.5%
Return on invested capital
-10.3%
Return on capital employed
-5.6%
Return on sales
-741.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XFOR stock price
How has the X4 Pharmaceuticals stock price performed over time
Intraday
8.23%
1 week
-10.15%
1 month
-25.73%
1 year
-54.01%
YTD
-56.06%
QTD
-44.96%
Financial performance
How have X4 Pharmaceuticals's revenue and profit performed over time
Revenue
$1.12M
Gross profit
$628,000
Operating income
-$25.89M
Net income
-$16.76M
Gross margin
55.9%
Net margin
-1,492.3%
X4 Pharmaceuticals's net income has plunged by 195% from the previous quarter but it has soared by 85% YoY
The net margin has plunged by 148% from the previous quarter
X4 Pharmaceuticals's gross profit has soared by 113% from the previous quarter
The revenue has surged by 99% since the previous quarter
Growth
What is X4 Pharmaceuticals's growth rate over time
Valuation
What is X4 Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.04
P/S
65.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.84
The EPS has dropped by 189% since the previous quarter but it has soared by 89% year-on-year
The stock's price to book (P/B) is 98% less than its last 4 quarters average of 57.7 and 92% less than its 5-year quarterly average of 12.8
The equity has contracted by 37% from the previous quarter and by 12% YoY
The revenue has surged by 99% since the previous quarter
Efficiency
How efficient is X4 Pharmaceuticals business performance
The company's return on equity has shrunk by 199% QoQ but it has surged by 81% YoY
XFOR's return on assets has dropped by 194% since the previous quarter but it has surged by 85% year-on-year
XFOR's return on invested capital has dropped by 128% since the previous quarter but it has surged by 96% year-on-year
The ROS has dropped by 116% since the previous quarter
Dividends
What is XFOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XFOR.
Financial health
How did X4 Pharmaceuticals financials performed over time
XFOR's total assets is 50% greater than its total liabilities
The quick ratio has declined by 21% since the previous quarter and by 17% year-on-year
The company's current ratio fell by 19% QoQ and by 16% YoY
The debt is 31% more than the equity
X4 Pharmaceuticals's debt to equity has soared by 58% from the previous quarter and by 52% YoY
The equity has contracted by 37% from the previous quarter and by 12% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.